The pleiotropic effects of angiotensin receptor blockers
- PMID: 16596029
- PMCID: PMC8109722
- DOI: 10.1111/j.1524-6175.2005.05264.x
The pleiotropic effects of angiotensin receptor blockers
Abstract
The angiotensin receptor blockers (ARBs) are very effective and safe antihypertensive drugs. They exert their antihypertensive effect through blockage of the angiotensin II, type 1 receptor and quite possibly through stimulation by angiotensin II of the unoccupied type 2 receptor. Besides hypertension, the ARBs have been found recently to be of value in the treatment of heart failure and diabetic nephropathy. In addition, ARBs have emerged lately as being very effective and perhaps superior to other antihypertensive drugs in the prevention of de novo or recurrent strokes. Other actions that may account for their stroke-protective effects include their antiatherogenic, antidiabetic, antiplatelet aggregating, hypouricemic, and atrial antifibrillatory actions. All these actions make the ARBs a true pleiotropic class of drugs. Each of the foregoing effects will be discussed briefly in this concise review.
Similar articles
-
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.Cardiovasc Diabetol. 2013 Nov 4;12:159. doi: 10.1186/1475-2840-12-159. Cardiovasc Diabetol. 2013. PMID: 24180232 Free PMC article.
-
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.Prescrire Int. 2005 Oct;14(79):180-6. Prescrire Int. 2005. PMID: 16285075
-
The impact of suppressing the renin-angiotensin system on atrial fibrillation.J Clin Pharmacol. 2006 Jan;46(1):21-8. doi: 10.1177/0091270005283284. J Clin Pharmacol. 2006. PMID: 16397280
-
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.Postgrad Med. 2001 Apr;109(4):115-22; quiz 9. doi: 10.3810/pgm.2001.04.911. Postgrad Med. 2001. PMID: 11317462 Review.
-
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.Pharmacol Res. 2002 Sep;46(3):203-12. doi: 10.1016/s1043-6618(02)00092-0. Pharmacol Res. 2002. PMID: 12220962 Review.
Cited by
-
Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons learned for losartan: An "old dog playing good tricks".J Clin Hypertens (Greenwich). 2018 Jun 15;20(8):1153-9. doi: 10.1111/jch.13325. Online ahead of print. J Clin Hypertens (Greenwich). 2018. PMID: 29907995 Free PMC article. Review.
-
Hypertension in patients on dialysis: diagnosis, mechanisms, and management.J Bras Nefrol. 2019 Jul-Sep;41(3):400-411. doi: 10.1590/2175-8239-jbn-2018-0155. Epub 2018 Nov 8. J Bras Nefrol. 2019. PMID: 30421784 Free PMC article. Review.
-
The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition.BMC Geriatr. 2009 Nov 18;9:48. doi: 10.1186/1471-2318-9-48. BMC Geriatr. 2009. PMID: 19922631 Free PMC article. Clinical Trial.
-
An update on the cardiovascular pleiotropic effects of milk and milk products.J Clin Hypertens (Greenwich). 2013 Jul;15(7):503-10. doi: 10.1111/jch.12110. Epub 2013 Apr 29. J Clin Hypertens (Greenwich). 2013. PMID: 23815539 Free PMC article. Review.
-
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.BMJ. 2009 May 19;338:b1665. doi: 10.1136/bmj.b1665. BMJ. 2009. PMID: 19454737 Free PMC article. Review.
References
-
- Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother. 2004;5:657–667. - PubMed
-
- Chrysant SG, Chrysant GS. Clinical experience with angiotensin receptor blockers with particular reference to valsartan. J Clin Hypertens (Greenwich). 2004;6:445–451. - PubMed
-
- Chrysant SG, Chrysant GS, Desai A. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J Hum Hypertens. 2005;19:173–183. - PubMed
-
- Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003. - PubMed
-
- Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022–2031. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources